Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrobial Agents and Chemotherapy

The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90 % of the isolates tested were inhibited [MIC90s], <1 g/ml). In addition, it was also very potent against most members of the Enterobac-teriaceae, with most MIC90s being <2 g/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomo-nas maltophilia are included in the in vitro spectrum of tigecycline activity. Although tetracyclines remain valuable therapeutic agents for a variety of infections, resistance to this class limits their use. A new generation of tetracyclines, the glycylcyclines, is being developed specifically to overcome the problem of resis-tance to other tetracyclines (4, 16). Tigecycline (GAR-936), the 9-t-butylglycylamido derivative of minocycline, appears to be both better tolerated and more active against tetracycline-resistant strains than are other glycylcyclines (14). The present study examined the in vitro activities of tigecycline and com-parators against recent clinical isolates from various Europea